2017 American Society of Hematology Annual Meeting*

Download All
December 9-12, 2017; Atlanta, Georgia
Shaji Kumar, MD, and Sagar Lonial, MD, review and share their expert perspectives on key findings in multiple myeloma presented at the 2017 ASH annual meeting.
Shaji K. Kumar, MD
Sagar Lonial, MD

Multiple Myeloma

This prospective subanalysis of the phase III EMN02/HO95 trial suggests benefit in PFS and OS with double ASCT, particularly for patients with high-risk MM.

Released: December 14, 2017

The use of KRd induction plus transplantation and consolidation resulted in a CR or better in approximately 75% of patients with high-risk smoldering myeloma with an acceptable safety profile.

Released: December 12, 2017

BCMA-CART with or without cyclophosphamide lymphodepletion demonstrates promising clinical activity in heavily pretreated patients with MM.

Released: December 12, 2017

Combined infusion of CD19- and BCMA-specific CAR T-cells generally well tolerated and produces high remission rates in patients with relapsed/refractory multiple myeloma.

Released: December 14, 2017

Daratumumab monotherapy demonstrated clinical activity and a favorable safety profile in patients with intermediate- and high-risk smoldering multiple myeloma.

Released: December 15, 2017

Extended follow-up continues to demonstrate significant increase in PFS with addition of daratumumab to lenalidomide/dexamethasone for patients with relapsed/refractory myeloma.

Released: December 19, 2017

Results from the dose escalation show that second-generation bb2121 CAR T-cell therapy yielded a 94% ORR and a 56% CR rate in heavily pretreated patients with relapsed/refractory MM.

Released: December 14, 2017

A new human scFv-derived BCMA-targeted CAR T-cell appears tolerable with no reported dose-limiting toxicity and preliminary evidence of activity in patients with heavily pretreated myeloma.

Released: December 15, 2017

In evaluable patients who relapsed following initial RVD therapy (with or without upfront ASCT), 4 cycles of PCD yielded an ORR of 85% with 95% of transplant-naive patients proceeding to a first ASCT.

Released: December 12, 2017

The use of manual subcutaneous injection of coformulation of daratumumab and rHuPH20 enabled short administration, was well tolerated, and demonstrated a response rate similar to IV daratumumab.

Released: December 15, 2017

Use of elotuzumab/lenalidomide/dexamethasone maintenance therapy following autologous stem cell transplantation in patients with multiple myeloma improved quality of response in 36% of patients in this preliminary analysis.

Released: December 18, 2017

Among patients with newly diagnosed MM not undergoing ASCT, ixazomib-based induction followed by ixazomib maintenance therapy was associated with an ORR of 94%, including a CR rate of 35%.

Released: December 18, 2017

In this online course, Shaji Kumar, MD, and Sagar Lonial, MD, discuss the results and provide their perspective on the clinical applicability of key multiple myeloma studies presented at the Hematology 2017 annual meeting.

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 3.0 AMA PRA Category 1 Credits Released: March 14, 2018 Expired: No longer available for credit

The combination of daratumumab plus VMP reduced the risk of progression or death by 50% vs VMP alone in transplantation-ineligible patients with newly diagnosed myeloma in this randomized, open-label phase III study.

Released: December 13, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Celgene Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics Inc.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings